Education
About Us
Working with TipRanks
Follow Us
Pharming Group N.V. (DE:PHGN)
XETRA:PHGN
PHGN Stock Chart & Stats
€1.42
€0.01(1.21%)
At close: 4:00 PM EST
€1.42
€0.01(1.21%)
Day’s Range― - ―
52-Week Range€0.67 - €2.45
Previous CloseN/A
Volume0.00
Average Volume (3M)11.21K
Market Cap
€1.01B
Enterprise Value€1.19B
Total Cash (Recent Filing)€166.17M
Total Debt (Recent Filing)€130.92M
Price to Earnings (P/E)―
Beta0.55
Next Earnings
Mar 12, 2026EPS Estimate
<0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)<0.01
Shares Outstanding701,404,050
10 Day Avg. Volume3,832
30 Day Avg. Volume11,210
Financial Highlights & Ratios
PEG Ratio-2.95
Price to Book (P/B)2.98
Price to Sales (P/S)2.22
P/FCF Ratio-255.48
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue Growth & Upgraded GuidanceA 30% quarterly revenue increase and upgraded full-year guidance indicate durable demand for Ruconest and Joenja. This supports scale economics, improves planning visibility for R&D and commercial investment, and underpins multi-quarter revenue predictability for a rare-disease specialty company.
High Gross Margins And Strong FCFVery high gross margins (~90%) reflect pricing power and efficient biologics manufacturing, while near-doubling free cash flow shows improved cash conversion. Together these sustain funding for pipeline programs and commercialization without immediate reliance on dilutive financing, supporting multi-quarter operational resilience.
Improved Leverage And Balance SheetA lower debt-to-equity ratio (0.49) signals reduced financial risk and greater flexibility to invest in late-stage trials or geographic expansion. Improved capital structure enhances the company’s ability to absorb setbacks, fund strategic initiatives, and pursue partnerships over the coming 2-6 months.
Bears Say
Very Weak Net ProfitabilityDespite revenue gains, negligible net margin and near-zero ROE show limited ability to convert sales into retained earnings. Persistently low profitability constrains internal funding for R&D, increases reliance on external capital for growth, and raises execution risk across upcoming quarters.
RUCONEST Market WithdrawalsWithdrawing RUCONEST from some European markets is a structural commercial contraction that reduces addressable market and patient access. It can lower long-term revenue diversification, concentrate sales in fewer markets, and increase sensitivity to pricing or reimbursement in remaining territories.
FDA CRL For Joenja Pediatric SNDAA CRL requiring additional pediatric PK data and analytical clarifications delays U.S. label expansion for Joenja. This regulatory setback can postpone pediatric market revenue, extend development costs, and push back strategic milestones central to medium-term growth and commercialization plans.
Pharming Group News
PHGN FAQ
What was Pharming Group N.V.’s price range in the past 12 months?
Pharming Group N.V. lowest stock price was €0.67 and its highest was €2.45 in the past 12 months.
What is Pharming Group N.V.’s market cap?
Pharming Group N.V.’s market cap is €1.01B.
When is Pharming Group N.V.’s upcoming earnings report date?
Pharming Group N.V.’s upcoming earnings report date is Mar 12, 2026 which is in 14 days.
How were Pharming Group N.V.’s earnings last quarter?
Pharming Group N.V. released its earnings results on Nov 06, 2025. The company reported €0.008 earnings per share for the quarter, beating the consensus estimate of €0 by €0.008.
Is Pharming Group N.V. overvalued?
According to Wall Street analysts Pharming Group N.V.’s price is currently Overvalued.
Does Pharming Group N.V. pay dividends?
Pharming Group N.V. does not currently pay dividends.
What is Pharming Group N.V.’s EPS estimate?
Pharming Group N.V.’s EPS estimate is <0.01.
How many shares outstanding does Pharming Group N.V. have?
Pharming Group N.V. has 701,404,050 shares outstanding.
What happened to Pharming Group N.V.’s price movement after its last earnings report?
Pharming Group N.V. reported an EPS of €0.008 in its last earnings report, beating expectations of €0. Following the earnings report the stock price went up 23.529%.
Which hedge fund is a major shareholder of Pharming Group N.V.?
Currently, no hedge funds are holding shares in DE:PHGN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Pharming Group N.V.
Pharming Group N.V., a biopharmaceutical company, develops and commercialize protein replacement therapies and precision medicines for the treatment of rare diseases and unmet medical needs in the United States, Europe, and internationally. The company's lead product is Ruconest, a recombinant human C1 esterase inhibitor that is used for the treatment of acute hereditary angioedema. It also engages in the development of rhC1INH for the treatment of pre-eclampsia, acute kidney injury, and COVID-19; leniolisib, a phosphoinositide 3-kinase delta (PI3K delta) to treat patients with activated PI3K delta syndrome; and alpha-glucosidase therapy for the treatment of pompe and fabry diseases. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of hereditary angioedema. Pharming Group N.V. is headquartered in Leiden, the Netherlands.
PHGN Company Deck
PHGN Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted strong financial performance with significant revenue growth and upgraded guidance. RUCONEST and Joenja both showed robust performance, and the company's cash position has been restored. However, there is a planned withdrawal of RUCONEST from certain markets due to financial sustainability concerns. Overall, the positive aspects significantly outweigh the lowlight.View all DE:PHGN earnings summariesTechnical Analysis
Options Prices
Currently, No data available
---